Rhythm Pharmaceuticals, Inc.
RYTM
$103.94
$2.552.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.92% | 53.55% | 48.88% | 68.06% | 81.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.92% | 53.55% | 48.88% | 68.06% | 81.55% |
| Cost of Revenue | 44.18% | 47.43% | 32.95% | 43.72% | 80.57% |
| Gross Profit | 56.30% | 54.32% | 50.98% | 71.38% | 81.67% |
| SG&A Expenses | 26.74% | 18.63% | 17.07% | 22.78% | 24.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.22% | 21.37% | 14.10% | 15.83% | 15.56% |
| Operating Income | -7.56% | -2.46% | 3.73% | 6.10% | 6.52% |
| Income Before Tax | 25.70% | 29.06% | 38.26% | -41.34% | -39.48% |
| Income Tax Expenses | -30.59% | -101.27% | -85.53% | -38.83% | 71.47% |
| Earnings from Continuing Operations | 25.72% | 29.44% | 38.40% | -41.09% | -39.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.72% | 29.44% | 38.40% | -41.09% | -39.54% |
| EBIT | -7.56% | -2.46% | 3.73% | 6.10% | 6.52% |
| EBITDA | -7.72% | -2.55% | 3.67% | 6.05% | 6.48% |
| EPS Basic | 28.47% | 30.88% | 39.30% | -35.92% | -33.11% |
| Normalized Basic EPS | -4.06% | -0.03% | 6.93% | 9.36% | 11.02% |
| EPS Diluted | 28.47% | 30.88% | 39.30% | -35.92% | -33.11% |
| Normalized Diluted EPS | -4.06% | -0.03% | 6.93% | 9.36% | 11.02% |
| Average Basic Shares Outstanding | 5.39% | 4.75% | 5.46% | 5.77% | 6.07% |
| Average Diluted Shares Outstanding | 5.39% | 4.75% | 5.46% | 5.77% | 6.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |